Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent "FF-10501" For FUJIFILM In Patients With Advanced Hematologic Malignancies
9/2/2014 1:31:26 PM
BOSTON--(BUSINESS WIRE)--Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS). The trial is carried out at the University of Texas MD Anderson Cancer Center (MD Anderson) with Guillermo Garcia-Manero, M.D., Professor, as the Principal Investigator. Prof. Garcia-Manero is a world-renowned expert in advanced hematologic malignancies, especially MDS.
Help employers find you! Check out all the jobs and post your resume.
comments powered by